Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nature Medicine publication: Early anakinra treatment for COVID-19 guided by suPAR saves lives

11/29/2021 | 07:21am EST

An early increase of suPAR serum levels indicates an increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure.

Key highlights from the study

• Results showed a 70% decrease in the relative risk of progression to severe respiratory failure and a significant reduction in 28-d mortality with anakinra treatment compared to standard of care.
• Relative decrease of mortality was 55%, reaching 80% for patients with cytokine storm.
• Average time until hospital and intensive care unit (ICU) discharge was reduced by one to four days.

Method

From 23 December 2020 to 31 March 2021, 1,060 patients positively diagnosed with Covid-19 were screened, and 594 (excluding those at low risk based on low suPAR results) were randomized at 37 study sites. The SAVE-MORE study, conducted by the Hellenic Institute for the Study of Sepsis, is the first large, pivotal randomized controlled trial to specifically evaluate a patient population triaged, when at risk of progressing to a critical state using suPARnostic®. The study demonstrates the considerable benefit of earlier intervention for the prevention of disease progression and death.
189 patients were allocated to the placebo arm, and 405 patients were allocated to the anakinra arm. Baseline characteristics and co-administered treatments were similar between the two treatment arms. Overall, 91.6% of patients had severe pneumonia as defined by the WHO classification for COVID-19. On day 28, the adjusted proportional odds of having a worse clinical status with anakinra, as compared to placebo, was 0.36. Twenty-eight-day mortality decreased, and hospital stay was shorter.

Disclaimer

ViroGates A/S published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 12:20:09 UTC.


ę Publicnow 2021
All news about VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More news
Financials
Sales 2020 5,35 M 0,82 M 0,82 M
Net income 2020 -18,7 M -2,86 M -2,86 M
Net cash 2020 33,5 M 5,11 M 5,11 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 504 M 76,8 M 76,8 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float -
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S10.42%77
EXACT SCIENCES CORPORATION-4.88%12 757
GUARDANT HEALTH, INC.-29.91%7 126
BGI GENOMICS CO., LTD.1.37%5 755
SEEGENE, INC.-1.31%2 606
INVITAE CORPORATION-29.21%2 447